Report Buyer, the online destination for business intelligence for major industry sectors, has now added a new report showing that although the overall annual growth of prescription pediatric drugs is forecast at a modest 3.2%, reaching $43 billion by 2011. The hormone drug segment, with a current market share of 11.7%, is expected to achieve the highest growth rate of 8.3% during the same time period.

Pediatric Drugs: the Worldwide Market reports that the high growth rate of the prescription hormone drug segment in the pediatric population, both domestic and worldwide, can be attributed to an increase in the incidence of diabetes, thyroid conditions, and growth disorders, as well as improved screening procedures, better products, availability, effectiveness, education and delivery techniques suitable for
children.

Within the hormone segment, the highest growth rates are for antidiabetic agents and growth hormone drugs, at 9.1% and 14.4% respectively from 2004 to 2006 and estimated at 5.4% and 10.8% between 2006 and 2011.

Authors of the report note that while the focus of most healthcare watchers has been the aging of the world population, one must not forget that children number nearly 2.5 billion, or 40% of the humans on the planet.

“Pediatric Drugs: the Worldwide Market” covers anti-infectives, cancer therapies, and drugs for allergy, respiratory, cardiovascular, central nervous system, gastrointestinal and hormone treatments. Each section of the report details products, market estimates, forecasts through to 2011 and competitive analyses of leading providers. Extensive tables of products in research and development and in-depth discussions of current and future issues and trends are also included, with additional insight from more than 100 interviews with key industry experts.

Pediatric Drugs: the Worldwide Market

Report Buyer product ID: KAL00107
Report Buyer Category: Pharma and Healthcare